KLOW peptide,
explained in depth.
KLOW is a four-peptide blend combining BPC-157, GHK-Cu, TB-500, and KPV — four of the most studied regenerative peptides — into a single synergistic stack. Rather than running four separate protocols, KLOW delivers tissue repair, anti-inflammatory signaling, collagen synthesis, and immune modulation in one vial. This guide covers how the KLOW peptide blend works, what each ingredient does, dosing protocols, and what the research says about combining these compounds.
What is the KLOW peptide?
KLOW is a pre-formulated peptide blend designed for regenerative and recovery applications. The name represents the four compounds it contains: KPV, the anti-inflammatory tripeptide fragment of alpha-MSH; a copper tripeptide (L... more precisely, GHK-Cu, responsible for collagen and elastin synthesis); and two tissue-repair peptides — BPC-157 and TB-500 — that together form the core of the Wolverine Blend. The KLOW peptide is essentially the Wolverine Blend expanded with two additional compounds that address inflammation and skin/tissue remodeling.
The rationale for combining these four peptides is that biological repair is not a single-pathway event. When tissue is damaged — whether from injury, surgery, chronic inflammation, or normal aging — the body needs to simultaneously suppress excessive inflammation (KPV), recruit repair cells and build new blood vessels (BPC-157 and TB-500), and remodel the extracellular matrix with new collagen and elastin (GHK-Cu). Single-peptide protocols address one or two of these mechanisms. The KLOW peptide blend attempts to address all four simultaneously.
Each vial of KLOW typically contains 80 mg total: GHK-Cu at 50 mg (the largest component by mass, reflecting its role as the primary matrix-remodeling agent), BPC-157 at 10–15 mg, TB-500 at 10–15 mg, and KPV at 10 mg. The exact ratios may vary slightly between compounding pharmacies, but the 50/15/15/10 and 50/10/10/10 formulations are the most common.
KLOW peptide blend, covered in depth.
Ingredient breakdown, dosing protocols, benefits, side effects, and how KLOW compares to simpler peptide stacks.
What's in the KLOW blend
Deep dive into each of the four compounds — BPC-157, GHK-Cu, TB-500, and KPV — their mechanisms, doses, and what each brings to the blend.
Read the ingredient breakdown → 02 / 05KLOW peptide benefits
Tissue repair, inflammation reduction, gut healing, skin regeneration, hair growth, and recovery acceleration — mapped to the compounds that drive each benefit.
Read the benefits guide → 03 / 05KLOW dosing protocol
Reconstitution math for the 80 mg vial, titration schedule, injection sites, cycle length, and timing recommendations.
Read the dosing guide → 04 / 05KLOW side effects
Safety profile by compound: BPC-157 angiogenesis concerns, GHK-Cu copper considerations, TB-500 and cancer, KPV tolerability, and FDA regulatory status.
Read the side effects guide → 05 / 05KLOW vs Wolverine Blend
The Wolverine Blend is BPC-157 + TB-500. KLOW adds GHK-Cu and KPV. When the quad-stack is worth it vs the simpler two-peptide protocol.
Read the comparison →What's inside the KLOW peptide blend
| Compound | Dose per vial | Class | Primary mechanism |
|---|---|---|---|
| BPC-157 | 10–15 mg | Pentadecapeptide (15 amino acids) | Angiogenesis, tissue repair, gut healing via VEGFR2, NO, and FAK-paxillin pathways. The core repair engine of the blend. Full BPC-157 research guide → |
| GHK-Cu | 50 mg | Copper tripeptide (3 amino acids + Cu²⁺) | Collagen and elastin synthesis, wound remodeling, gene expression regulation. The matrix-rebuilding component. Full GHK-Cu research guide → |
| TB-500 | 10–15 mg | Synthetic thymosin beta-4 fragment (43 amino acids) | Cell migration, actin regulation, angiogenesis. Coordinates how repair cells move to injury sites and organize during healing. |
| KPV | 10 mg | Tripeptide (3 amino acids, α-MSH fragment) | Anti-inflammatory via NF-κB inhibition, pro-inflammatory cytokine suppression. Controls the inflammatory environment during repair. Full KPV research guide → |
The compound ratios in KLOW are not arbitrary. GHK-Cu is present at the highest dose (50 mg) because it has the shortest biological half-life of the four compounds and requires higher absolute amounts to maintain effective tissue concentrations. BPC-157 and TB-500 are dosed at 10–15 mg each — consistent with the standalone dosing used in the Wolverine Blend. KPV at 10 mg reflects the low doses at which alpha-MSH fragments produce anti-inflammatory effects in published research. For a detailed breakdown of each compound's mechanism and published research, see the KLOW ingredients page.
KLOW peptide FAQ
What is the KLOW peptide used for?
KLOW is used in regenerative and recovery protocols where multiple biological pathways need to be addressed simultaneously. Common applications include post-injury recovery (muscle, tendon, ligament), gut healing and inflammatory bowel support, skin repair and anti-aging, post-surgical recovery, and general tissue regeneration. The four-compound blend is designed to suppress inflammation (KPV), initiate tissue repair (BPC-157), coordinate cell migration and blood vessel formation (TB-500), and rebuild the extracellular matrix (GHK-Cu) in a single protocol. See the KLOW benefits page for a detailed breakdown.
How is the KLOW peptide blend administered?
KLOW is administered as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. The lyophilized powder is reconstituted with bacteriostatic water before use. Standard protocols call for once-daily injection. See the KLOW dosing page for the full reconstitution math and titration schedule.
Is KLOW the same as the Wolverine Blend?
No. The Wolverine Blend contains two peptides — BPC-157 and TB-500. KLOW contains four — BPC-157, TB-500, GHK-Cu, and KPV. KLOW is an expanded version that adds matrix remodeling (GHK-Cu) and anti-inflammatory signaling (KPV) to the Wolverine Blend's tissue-repair foundation. See the KLOW vs Wolverine Blend comparison for a full breakdown.
Is KLOW peptide FDA-approved?
No. KLOW is not FDA-approved for any indication. Two of its four components — BPC-157 and TB-500 — are on the FDA's Category 2 list of bulk drug substances that may present significant safety risks in compounding. GHK-Cu and KPV are not on the Category 2 list but are also not FDA-approved as therapeutic agents. KLOW is available through compounding pharmacies and research peptide suppliers but has not been reviewed by the FDA for safety, effectiveness, or quality.
Can you run BPC-157, GHK-Cu, TB-500, and KPV separately instead of KLOW?
Yes. Each compound in KLOW is available individually and can be run as a standalone protocol or combined by the user. The advantage of the KLOW blend is convenience (one vial, one injection) and pre-formulated ratios that ensure consistent dosing. The disadvantage is less flexibility — you cannot adjust the dose of one compound without changing the others. For deep dives on individual compounds, see the research guides for BPC-157, GHK-Cu, and KPV.